Managing Obesity in Heart Failure: Latest Evidence and Knowledge Gaps
Authors:
Open Access
- 28 August 2024
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 26 (12) , 355-367
Abstract
Purpose of Review: This review aims to synthesize the latest evidence focused on therapies related to comorbid obesity and heart failure, with particular attention to lifestyle, pharmacological, and surgical modalities. Recent Findings: Obesity is a common risk factor for heart failure, which can also exacerbate symptom burden of heart failure. Emerging treatments, such as the use of GLP-1 analogs like semaglutide, have shown promising results in improving symptoms and physical limitations in the setting of comorbid heart failure with preserved ejection fraction and obesity. Conversely, the efficacy of such treatments in heart failure with reduced ejection fraction remains uncertain, with some studies suggesting potential adverse outcomes. Lifestyle interventions, including dietary changes and structured exercise programs, may be associated with benefits in terms of functional capacity and symptom burden, and retrospective cohort studies of surgical weight loss have raised the possibility of improvements in medium term survival for patients with baseline HF, challenging the previous notions of the "obesity survival paradox”. Summary: The management of comorbid obesity and heart failure is a rapidly evolving field. The interplay of pharmacological, lifestyle, and surgical interventions highlights the need for personalized treatment plans to mitigate the risks and enhance the quality of life for patients with heart failure. It is hoped that future guidelines will integrate these findings to address the nuances of optimally treating both heart failure and obesity in patients with both conditions. GraphicalKeywords
This publication has 79 references indexed in Scilit:
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Sleeve gastrectomy facilitates weight loss and permits cardiac transplantation in patients with severe obesity and a left ventricular assist device (LVAD)Surgical Endoscopy, 2023
- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and ObesityJAMA Network Open, 2021
- Sleeve Gastrectomy in Patients with Continuous-Flow Left Ventricular Assist Devices: a Systematic Review and Meta-AnalysisObesity Surgery, 2020
- Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart FailureJAMA Cardiology, 2020
- The effect of protein and essential amino acid supplementation on muscle strength and performance in patients with chronic heart failure: a systematic reviewEuropean Journal of Nutrition, 2019
- Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled TrialEuropean Journal of Heart Failure, 2016
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection FractionJAMA, 2016
- Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection FractionJAMA, 2016
- Efficacy and Safety of Exercise Training in Patients With Chronic Heart FailureJAMA, 2009